Iron Mediated Vascular Disease in Sickle Cell Anemia Patients

Iron-mediated Vascular Disease in Sickle Cell Disease.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01239901

Enrollment

150

Registered

2010-11-15

Start date

2009-12-31

Completion date

2018-10-31

Last updated

2019-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sickle Cell Disease

Keywords

sickle cell disease, sickle cell anemia, sickled cells, blood vessel, iron overload

Brief summary

The purpose of this research study is to determine the frequency and severity of iron overload in patients with Sickle Cell Anemia and its relationship to blood vessel function. The investigators hypothesize that intermittent transfusions that these patients receive during hospitalizations produces significant iron overload and impairs blood vessel relaxation.

Detailed description

Patients with sickle cell anemia often require blood transfusion as part of the treatment for their disease. Each teaspoon of transfused blood contains about 5 mg of iron and the levels of iron in sickle cell patients increase rapidly with each transfusion. While iron is necessary for many bodily functions, too much iron damages blood vessels, liver, hormone producing glands (pancreas, pituitary and thyroid) and the heart. It is important to know how iron damages blood vessels because most of the problems experienced by sickle cell anemia patients (stroke, kidney failure, pulmonary hypertension, heart disease) result from blood vessel damage. In this trial, iron in the liver, pancreas, and kidney will be measured noninvasively by MRI while vascular function will be measured by ultrasound and tissue Doppler. Patients will be recruited primarily from the greater Los Angeles area, although patients from greater distances will be allowed to participate.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

13 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age \> 13 years * Documented diagnosis of sickle cell anemia (SS, SC, Sß0, Sß+) * Transfused no more than 8 times in a year.

Exclusion criteria

* Cardiac pacemaker, implantable neurostimulator or other MRI incompatible device. * History of extreme claustrophobia in MRI machine or other reason for inability to do MRI without sedation. * Inability to be positioned on the MRI table for sufficient time to complete the MRI exams. * Any medical or psychological condition that, in the opinion of the local investigator, would make it unsafe or ill-advised for the subject to participate. * Currently not receiving chronic transfusion therapy, defined as greater than 8 transfusions per year.

Design outcomes

Primary

Measure	Time frame	Description
Liver iron concentration (LIC), pancreas R2, and kidney R2, measured by MRI	15 min MRI done completed during one time study visit	Liver iron concentration (LIC) will be used as a surrogate for total body iron, pancreatic iron represents a surrogate for extravascular iron deposition, and renal iron as a surrogate for chronic intravascular hemolysis. In addition, labile plasma iron will be measured in blood plasma.

Secondary

Measure	Time frame	Description
Vascular function.	Scheduled during one time study visit	Measurements will be done through several procedures: Ultrasound of artery in upper arm, Ultrasound of artery in neck, and blood tests of ascorbate and hydrobiopterins.

Countries

United States

Outcome results